AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 292 min read$MBRX

Moleculin Completes Part A Enrollment In Phase 2/3 MIRACLE Trial For Relapsed AML

Moleculin Biotech (MBRX) completed Part A enrollment in its Phase 2/3 MIRACLE trial for relapsed AML, with 89 participants. The trial evaluates Annamycin plus cytarabine. Results are expected in Q1 2027. No cardiotoxicity observed. MBRX stock is currently at $0.56.

Original reporting
rttnews.com
Published Sep 29, 2026, 3:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 29, 2026, 7:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$MBRX
Neutral
high confidence
Mentioned
$MBRX
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$MBRXNeutralMed
01

Why it matters

The completion of Part A enrollment removes a key development hurdle and signals that the trial is on schedule, which can reduce downside risk and attract speculative interest ahead of the data readout.

02

Market read

While the news is not a catalyst for immediate large‑scale price movement, it provides a fresh data point for traders monitoring early‑stage biotech trials.

03

What to watch

Potential regulatory delays or safety concerns not yet disclosed could dampen upside despite enrollment progress.

Relevance 7/10Novelty 7/10Timing: pre‑Q1 2027 data release

Background

Moleculin Biotech (NASDAQ: MBRX) is a micro‑cap company focused on novel anthracycline therapies for acute myeloid leukemia. The MIRACLE trial evaluates Annamycin plus cytarabine versus control.

Company-level read

Ticker impact

$MBRXNeutralHigh confidence
Context

Moleculin Biotech announced completion of Part A enrollment in its Phase 2/3 MIRACLE AML trial, a first‑time disclosure of this milestone.

Expected impact

potential modest upside as investors price in upcoming efficacy readout

Evidence & confidence

The news is new and material for a micro‑cap biotech; no data yet, but trial progress typically supports the share price ahead of readout.

Market effects

Sector

May lift sentiment in the AML/hematology biotech niche and could benefit peer companies developing similar anthracycline therapies.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Low global impact; relevance confined to specialty oncology investors.

Counterpoint

What could challenge this read

If the upcoming Part A readout fails to show clear efficacy, the enrollment news could be a false positive and the stock may face a sharp correction.

Key entities

  • Company
    Moleculin Biotech

    Developer of Annamycin, listed on Nasdaq under MBRX.

Read at source← All news

Related articles

SEP 29
$MBRXLow

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto

SEC EDGAR 8-K2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data

Moleculin Biotech (MBRX) published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine, showing no cardiotoxicity in 90 patients treated with Annamycin across five trials. The study, evaluated by Cleveland Clinic, found no significant changes in left ventricular ejection fraction (LVEF) and no treatment-related cardiotoxicity. Annamycin is being evaluated in the MIRACLE trial for relapsed or refractory AML.

rttnews.com2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Reports Cardiac Safety Findings For Annamycin In Pooled Analysis

Moleculin Biotech (MBRX) published cardiac safety findings for Annamycin, showing no evidence of cardiotoxicity in 90 patients across five trials. Mean LVEF remained stable, and no relationship was found between cumulative Annamycin exposure and LVEF changes. The analysis supports continued clinical evaluation of Annamycin, which is being studied in the MIRACLE trial for relapsed or refractory AML. MBRX stock closed at $0.60, up 6.12%, and is currently down 1.26% in pre-market trading.

rttnews.com2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine – Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding tradition

SEC EDGAR 8-K2 min
SEP 25
$MBRXMedAI 8/10

Moleculin Biotech, Inc. (MBRX): Annamycin Turns “Cold” Pancreatic Tumors “Hot” in New Preclinical Data Presented at AACR

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Annamycin Turns “ Cold ” Pancreatic Tumors “ Hot ” in New Preclinical Data Presented at AACR Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin ’ s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-medi

SEC EDGAR 8-K1 min
AUG 31
$MBRXMedAI 8/10

MBRX Stock Drops 25% As Moleculin Biotech's Interim Cancer Trial Data Falls Short Of Significance

Moleculin Biotech (MBRX) shares dropped 25% after interim trial data for Annamycin in AML patients showed no statistical significance, though remission rates were higher than standard chemotherapy. The MIRACLE trial continues with 67 of 90 patients enrolled. The company has $10.317M in cash, expected to last until Q3 2026. CEO Klemp called results encouraging but noted more data is needed.

stocktwits.com2 min